T3	eligibility 626 669	breast cancer patients with bone metastases
T4	control 713 720	placebo
T1	intervention 32 47	ibandronic acid
T5	total-participants 1016 1018	62
T6	outcome 1456 1477	treatment-related AEs
T7	cv-bin-percent 1529 1533	6.3%
T8	cv-bin-abs 1535 1536	1
T9	control-participants 1537 1539	16
T10	iv-bin-percent 1551 1556	13.0%
T11	iv-bin-abs 1558 1559	6
T12	intervention-participants 1560 1562	46
T13	outcome 1492 1514	in the extension phase
T14	outcome 1570 1590	in the initial phase
T15	cv-bin-percent 1614 1619	56.3%
T16	cv-bin-abs 1621 1622	9
T17	control-participants 1623 1625	16
T18	iv-bin-percent 1633 1638	67.4%
T19	iv-bin-abs 1640 1642	31
T20	intervention-participants 1643 1645	46
T2	outcome 1657 1660	AEs
T21	outcome 1738 1747	renal AEs
T22	outcome 1769 1792	serum creatinine levels
